Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Lung Cancer

Free Subscription Articles published in Cancer Chemother Pharmacol Retrieve available abstracts of 94 articles: HTML format

Single Articles

April 2021
1. LIU M, Yan Q, Peng B, Cai Y, et al
   Use of cucurbitacins for lung cancer research and therapy.
   Cancer Chemother Pharmacol. 2021 Apr 6. pii: 10.1007/s00280-021-04265.
   PubMed     Abstract available
   
   
   February 2021
2. LI C, Hart L, Owonikoko TK, Aljumaily R, et al
   Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage small cell lung cancer.
   Cancer Chemother Pharmacol. 2021 Feb 17. pii: 10.1007/s00280-021-04239.
   PubMed     Abstract available
   
   
   
3. CINIERO G, Elmenoufy AH, Gentile F, Weinfeld M, et al
   Enhancing the activity of platinum-based drugs by improved inhibitors of ERCC1-XPF-mediated DNA repair.
   Cancer Chemother Pharmacol. 2021;87:259-267.
   PubMed     Abstract available
   
   
   
4. YU S, Li Y, Ren H, Zhou H, et al
   PDK4 promotes tumorigenesis and cisplatin resistance in lung adenocarcinoma via transcriptional regulation of EPAS1.
   Cancer Chemother Pharmacol. 2021;87:207-215.
   PubMed     Abstract available
   
   
   January 2021
5. VERHEIJEN RB, van Duijl TT, van den Heuvel MM, Vessies D, et al
   Monitoring of EGFR mutations in circulating tumor DNA of non-small cell lung cancer patients treated with EGFR inhibitors.
   Cancer Chemother Pharmacol. 2021 Jan 23. pii: 10.1007/s00280-021-04230.
   PubMed     Abstract available
   
   
   
6. YAMAGATA A, Yokoyama T, Fukuda Y, Ishida T, et al
   Impact of interstitial lung disease associated with immune checkpoint inhibitors on prognosis in patients with non-small-cell lung cancer.
   Cancer Chemother Pharmacol. 2021 Jan 4. pii: 10.1007/s00280-020-04205.
   PubMed     Abstract available
   
   
   October 2020
7. HUANG J, Lin C, Dong H, Piao Z, et al
   Targeting MALAT1 induces DNA damage and sensitize non-small cell lung cancer cells to cisplatin by repressing BRCA1.
   Cancer Chemother Pharmacol. 2020 Oct 8. pii: 10.1007/s00280-020-04152.
   PubMed     Abstract available
   
   
   September 2020
8. FOURNEL L, Boudou-Rouquette P, Prieto M, Hervochon R, et al
   Nivolumab increases pulmonary artery pressure in patients treated for non-small cell lung cancer.
   Cancer Chemother Pharmacol. 2020 Sep 16. pii: 10.1007/s00280-020-04142.
   PubMed     Abstract available
   
   
   August 2020
9. KITO Y, Satake H, Taniguchi H, Yamada T, et al
   Phase Ib study of FOLFOXIRI plus ramucirumab as first-line treatment for patients with metastatic colorectal cancer.
   Cancer Chemother Pharmacol. 2020;86:277-284.
   PubMed     Abstract available
   
   
   
10. UCHINO T, Fujino H, Kamiya D, Suzuki T, et al
    Association of dry skin with intercellular lipid composition of stratum corneum after erlotinib administration.
    Cancer Chemother Pharmacol. 2020;86:233-243.
    PubMed     Abstract available
    
    
    
11. KAN M, Imaoka H, Watanabe K, Sasaki M, et al
    Chemotherapy-induced neutropenia as a prognostic factor in patients with pancreatic cancer treated with gemcitabine plus nab-paclitaxel: a retrospective cohort study.
    Cancer Chemother Pharmacol. 2020;86:203-210.
    PubMed     Abstract available
    
    
    July 2020
12. SHIMIZU T, Nishio K, Sakai K, Okamoto I, et al
    Phase I safety and pharmacokinetic study of YM155, a potent selective survivin inhibitor, in combination with erlotinib in patients with EGFR TKI refractory advanced non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2020 Jul 8. pii: 10.1007/s00280-020-04112.
    PubMed     Abstract available
    
    
    June 2020
13. CHEN J, Huang X, Tao C, Wang L, et al
    Berberine chloride suppresses non-small cell lung cancer by deregulating Sin3A/TOP2B pathway in vitro and in vivo.
    Cancer Chemother Pharmacol. 2020 Jun 30. pii: 10.1007/s00280-020-04050.
    PubMed     Abstract available
    
    
    
14. FUKUMOTO SI, Oizumi S, Harada M, Sukoh N, et al
    A randomized phase II trial of cisplatin plus gemcitabine versus carboplatin plus gemcitabine in patients with completely resected non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT0703).
    Cancer Chemother Pharmacol. 2020 Jun 20. pii: 10.1007/s00280-020-04104.
    PubMed     Abstract available
    
    
    
15. YI Y, Liu Z, Fang L, Li J, et al
    Comparison between single-agent and combination chemotherapy as second-line treatment for advanced non-small cell lung cancer: a multi-institutional retrospective analysis.
    Cancer Chemother Pharmacol. 2020 Jun 12. pii: 10.1007/s00280-020-04091.
    PubMed     Abstract available
    
    
    May 2020
16. HUIJBERTS SCFA, van Geel RMJM, van Brummelen EMJ, Opdam FL, et al
    Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer.
    Cancer Chemother Pharmacol. 2020;85:917-930.
    PubMed     Abstract available
    
    
    
17. LIU Y, Liu L, Liu L, Wang T, et al
    A phase I study investigation of metabolism, and disposition of [(14)C]-anlotinib after an oral administration in patients with advanced refractory solid tumors.
    Cancer Chemother Pharmacol. 2020;85:907-915.
    PubMed     Abstract available
    
    
    April 2020
18. LOMBARD A, Mistry H, Chapman SC, Gueoguieva I, et al
    Impact of tumour size measurement inter-operator variability on model-based drug effect evaluation.
    Cancer Chemother Pharmacol. 2020;85:817-825.
    PubMed     Abstract available
    
    
    March 2020
19. SHOJI T, Kikuchi E, Kikuchi J, Takashima Y, et al
    Evaluating the immunoproteasome as a potential therapeutic target in cisplatin-resistant small cell and non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2020 Mar 30. pii: 10.1007/s00280-020-04061.
    PubMed     Abstract available
    
    
    
20. YAMAGUCHI O, Imai H, Minemura H, Suzuki K, et al
    Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2020 Mar 19. pii: 10.1007/s00280-020-04055.
    PubMed     Abstract available
    
    
    
21. KIM SJ, Jegal KH, Im JH, Park G, et al
    Involvement of ER stress and reactive oxygen species generation in anti-cancer effect of CKD-516 for lung cancer.
    Cancer Chemother Pharmacol. 2020 Mar 11. pii: 10.1007/s00280-020-04043.
    PubMed     Abstract available
    
    
    February 2020
22. KAWAMURA T, Imamura CK, Kenmotsu H, Taira T, et al
    Evaluation of gefitinib systemic exposure in EGFR-mutated non-small cell lung cancer patients with gefitinib-induced severe hepatotoxicity.
    Cancer Chemother Pharmacol. 2020 Feb 10. pii: 10.1007/s00280-020-04034.
    PubMed     Abstract available
    
    
    
23. AHMAD Z, Jacobson BA, McDonald MW, Vattendahl Vidal N, et al
    Repression of oncogenic cap-mediated translation by 4Ei-10 diminishes proliferation, enhances chemosensitivity and alters expression of malignancy-related proteins in mesothelioma.
    Cancer Chemother Pharmacol. 2020;85:425-432.
    PubMed     Abstract available
    
    
    December 2019
24. AGULLO-ORTUNO MT, Garcia-Ruiz I, Diaz-Garcia CV, Enguita AB, et al
    Blood mRNA expression of REV3L and TYMS as potential predictive biomarkers from platinum-based chemotherapy plus pemetrexed in non-small cell lung cancer patients.
    Cancer Chemother Pharmacol. 2019 Dec 12. pii: 10.1007/s00280-019-04008.
    PubMed     Abstract available
    
    
    November 2019
25. LI CSW, Sweeney K, Cronenberger C
    Population pharmacokinetic modeling of PF-06439535 (a bevacizumab biosimilar) and reference bevacizumab (Avastin((R))) in patients with advanced non-squamous non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2019 Nov 26. pii: 10.1007/s00280-019-03946.
    PubMed     Abstract available
    
    
    
26. SCHETT A, Rothschild SI, Curioni-Fontecedro A, Krahenbuhl S, et al
    Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors : Antibiotics immune checkpoint inhibitors in advanced NSCLC.
    Cancer Chemother Pharmacol. 2019 Nov 19. pii: 10.1007/s00280-019-03993.
    PubMed     Abstract available
    
    
    
27. YAMAGUCHI O, Kaira K, Mouri A, Shiono A, et al
    Correction to: Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation.
    Cancer Chemother Pharmacol. 2019 Nov 8. pii: 10.1007/s00280-019-03984.
    PubMed     Abstract available
    
    
    September 2019
28. UEMURA T, Oguri T, Maeno K, Sone K, et al
    ABCC11 gene polymorphism as a potential predictive biomarker for an oral 5-fluorouracil derivative drug S-1 treatment in non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2019 Sep 17. pii: 10.1007/s00280-019-03959.
    PubMed     Abstract available
    
    
    
29. TANI T, Naoki K, Yasuda H, Arai D, et al
    A phase II trial of induction of erlotinib followed by cytotoxic chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer patients.
    Cancer Chemother Pharmacol. 2019 Sep 6. pii: 10.1007/s00280-019-03934.
    PubMed     Abstract available
    
    
    
30. SHIMADA M, Yamaguchi H, Fukuda M, Tomono H, et al
    Dose escalation study of amrubicin and cisplatin with concurrent thoracic radiotherapy for limited-disease small cell lung cancer.
    Cancer Chemother Pharmacol. 2019 Sep 5. pii: 10.1007/s00280-019-03940.
    PubMed     Abstract available
    
    
    August 2019
31. MOURI A, Kaira K, Yamaguchi O, Shiono A, et al
    Clinical difference between discontinuation and retreatment with nivolumab after immune-related adverse events in patients with lung cancer.
    Cancer Chemother Pharmacol. 2019 Aug 23. pii: 10.1007/s00280-019-03926.
    PubMed     Abstract available
    
    
    June 2019
32. ROYS A, Chang X, Liu Y, Xu X, et al
    Resistance mechanisms and potent-targeted therapies of ROS1-positive lung cancer.
    Cancer Chemother Pharmacol. 2019 Jun 29. pii: 10.1007/s00280-019-03902.
    PubMed     Abstract available
    
    
    
33. HOSOYA K, Fujimoto D, Kawachi H, Sato Y, et al
    Ineligibility for the PACIFIC trial in unresectable stage III non-small cell lung cancer patients.
    Cancer Chemother Pharmacol. 2019 Jun 14. pii: 10.1007/s00280-019-03885.
    PubMed     Abstract available
    
    
    
34. GOEL S, Swami U, Kumar K, Dittrich C, et al
    A phase 1b, multicenter, open-label, dose-finding study of eribulin in combination with carboplatin in advanced solid tumors and non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2019 Jun 12. pii: 10.1007/s00280-019-03877.
    PubMed     Abstract available
    
    
    May 2019
35. LIN S, Nickens DJ, Patel M, Wilner KD, et al
    Clinical implications of an analysis of pharmacokinetics of crizotinib coadministered with dexamethasone in patients with non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2019 May 24. pii: 10.1007/s00280-019-03861.
    PubMed     Abstract available
    
    
    April 2019
36. CHEN J, Liu B, Zhang F, Cui W, et al
    Pharmacokinetics and safety of lobaplatin plus etoposide in Chinese men older than 65 years with extensive-stage small cell lung cancer: a phase II clinical trial.
    Cancer Chemother Pharmacol. 2019 Apr 30. pii: 10.1007/s00280-019-03828.
    PubMed     Abstract available
    
    
    
37. LI Z, Wang M, Yu D, Luo W, et al
    Monomethyl auristatin E-conjugated anti-EGFR antibody inhibits the growth of human EGFR-positive non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2019 Apr 29. pii: 10.1007/s00280-019-03848.
    PubMed     Abstract available
    
    
    
38. MISTRY HB, Helmlinger G, Al-Huniti N, Vishwanathan K, et al
    Resistance models to EGFR inhibition and chemotherapy in non-small cell lung cancer via analysis of tumour size dynamics.
    Cancer Chemother Pharmacol. 2019 Apr 24. pii: 10.1007/s00280-019-03840.
    PubMed     Abstract available
    
    
    
39. KATO Y, Okuma Y, Watanabe K, Yomota M, et al
    A single-arm phase II trial of weekly nanoparticle albumin-bound paclitaxel (nab-paclitaxel) monotherapy after standard of chemotherapy for previously treated advanced non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2019 Apr 16. pii: 10.1007/s00280-019-03843.
    PubMed     Abstract available
    
    
    
40. KIVRAK SALIM D, Akin Telli T, Tatli AM, Kilickap S, et al
    Comparison of two different carboplatin and weekly paclitaxel schedule in elderly advanced non-small cell lung cancer patients.
    Cancer Chemother Pharmacol. 2019 Apr 9. pii: 10.1007/s00280-019-03839.
    PubMed     Abstract available
    
    
    
41. DE TROIA B, Dalu D, Filipazzi V, Isabella L, et al
    ABCB1 c.3435C>T polymorphism is associated with platinum toxicity: a preliminary study.
    Cancer Chemother Pharmacol. 2019;83:803-808.
    PubMed     Abstract available
    
    
    March 2019
42. KILICKAP S, Onder S, Dizdar O, Erman M, et al
    Short-time use of crizotinib as neoadjuvant in ALK-positive non-small cell lung carcinoma can be a chance for resectability.
    Cancer Chemother Pharmacol. 2019 Mar 12. pii: 10.1007/s00280-019-03810.
    PubMed     Abstract available
    
    
    
43. ZHOU H, Liu J, Zhang Y, Zhang L, et al
    Inflammatory bowel disease associated with the combination treatment of nivolumab and metformin: data from the FDA adverse event reporting system.
    Cancer Chemother Pharmacol. 2019;83:599-601.
    PubMed     Abstract available
    
    
    February 2019
44. KAWATA T, Higashimori M, Itoh Y, Tomkinson H, et al
    Gefitinib exposure and occurrence of interstitial lung disease in Japanese patients with non-small-cell lung cancer.
    Cancer Chemother Pharmacol. 2019 Feb 14. pii: 10.1007/s00280-019-03788.
    PubMed     Abstract available
    
    
    
45. YAMAGUCHI O, Kaira K, Mouri A, Shiono A, et al
    Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation.
    Cancer Chemother Pharmacol. 2019 Feb 13. pii: 10.1007/s00280-019-03790.
    PubMed     Abstract available
    
    
    
46. ALHARBI AF, Kratzke RA, D'Cunha J, Maddaus MA, et al
    Gemcitabine and metabolite pharmacokinetics in advanced NSCLC patients after bronchial artery infusion and intravenous infusion.
    Cancer Chemother Pharmacol. 2019;83:387-391.
    PubMed     Abstract available
    
    
    January 2019
47. KOSTEK O, Hacioglu MB, Sakin A, Demir T, et al
    Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer?
    Cancer Chemother Pharmacol. 2019;83:115-122.
    PubMed     Abstract available
    
    
    December 2018
48. GUSELLA M, Pasini F, Caruso D, Barile C, et al
    Clinical outcomes of oral metronomic vinorelbine in advanced non-small cell lung cancer: correlations with pharmacokinetics and MDR1 polymorphisms.
    Cancer Chemother Pharmacol. 2018 Dec 12. pii: 10.1007/s00280-018-3751.
    PubMed     Abstract available
    
    
    
49. QUAN YH, Lim JY, Choi BH, Choi Y, et al
    Self-targeted knockdown of CD44 improves cisplatin sensitivity of chemoresistant non-small cell lung cancer cells.
    Cancer Chemother Pharmacol. 2018 Dec 4. pii: 10.1007/s00280-018-3737.
    PubMed     Abstract available
    
    
    October 2018
50. HE Y, Xie H, Yu P, Jiang S, et al
    FOXC2 promotes epithelial-mesenchymal transition and cisplatin resistance of non-small cell lung cancer cells.
    Cancer Chemother Pharmacol. 2018 Oct 9. pii: 10.1007/s00280-018-3697.
    PubMed     Abstract available
    
    
    
51. ODA N, Hotta K, Ninomiya K, Minami D, et al
    A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403.
    Cancer Chemother Pharmacol. 2018 Oct 1. pii: 10.1007/s00280-018-3694.
    PubMed     Abstract available
    
    
    June 2018
52. HUANG C, Liu S, Tong X, Fan H, et al
    Extracellular vesicles and ctDNA in lung cancer: biomarker sources and therapeutic applications.
    Cancer Chemother Pharmacol. 2018 Jun 8. pii: 10.1007/s00280-018-3586.
    PubMed     Abstract available
    
    
    May 2018
53. MORCOS PN, Nueesch E, Jaminion F, Guerini E, et al
    Exposure-response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2018 May 10. pii: 10.1007/s00280-018-3597.
    PubMed     Abstract available
    
    
    
54. IMAI H, Minemura H, Sugiyama T, Yamada Y, et al
    Efficacy and safety of cytotoxic drug chemotherapy after first-line EGFR-TKI treatment in elderly patients with non-small-cell lung cancer harboring sensitive EGFR mutations.
    Cancer Chemother Pharmacol. 2018 May 8. pii: 10.1007/s00280-018-3596.
    PubMed     Abstract available
    
    
    
55. KOBA T, Minami S, Nishijima-Futami Y, Masuhiro K, et al
    Phase II trial of induction chemotherapy of pemetrexed plus split-dose cisplatin followed by pemetrexed maintenance for untreated non-squamous non-small-cell lung cancer.
    Cancer Chemother Pharmacol. 2018 May 4. pii: 10.1007/s00280-018-3598.
    PubMed     Abstract available
    
    
    
56. SMIT EF, Garon EB, Reck M, Cappuzzo F, et al
    Exposure-response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2018 May 2. pii: 10.1007/s00280-018-3560.
    PubMed     Abstract available
    
    
    April 2018
57. FUJITA K, Uchida N, Kanai O, Okamura M, et al
    Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases.
    Cancer Chemother Pharmacol. 2018 Apr 19. pii: 10.1007/s00280-018-3585.
    PubMed     Abstract available
    
    
    
58. NIHEI S, Sato J, Harada T, Kuyama S, et al
    Antiproteinuric effects of renin-angiotensin inhibitors in lung cancer patients receiving bevacizumab.
    Cancer Chemother Pharmacol. 2018 Apr 12. pii: 10.1007/s00280-018-3580.
    PubMed     Abstract available
    
    
    
59. FUKUSHIMA T, Wakatsuki Y, Kobayashi T, Sonehara K, et al
    Phase II study of cisplatin/pemetrexed combined with bevacizumab followed by pemetrexed/bevacizumab maintenance therapy in patients with EGFR-wild advanced non-squamous non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2018 Apr 11. pii: 10.1007/s00280-018-3573.
    PubMed     Abstract available
    
    
    February 2018
60. CUI J, Wang MC, Zhang YM, Ren MZ, et al
    Combination of S-1 and gefitinib increases the sensitivity to radiotherapy in lung cancer cells.
    Cancer Chemother Pharmacol. 2018 Feb 26. pii: 10.1007/s00280-018-3539.
    PubMed     Abstract available
    
    
    
61. SIENA L, Cipollina C, Di Vincenzo S, Ferraro M, et al
    Electrophilic derivatives of omega-3 fatty acids counteract lung cancer cell growth.
    Cancer Chemother Pharmacol. 2018 Feb 12. pii: 10.1007/s00280-018-3538.
    PubMed     Abstract available
    
    
    January 2018
62. TAIRA T, Yoh K, Nagase S, Kubota K, et al
    Long-term results of S-1 plus cisplatin with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer.
    Cancer Chemother Pharmacol. 2018 Jan 31. pii: 10.1007/s00280-018-3530.
    PubMed     Abstract available
    
    
    
63. WANG S, Gao A, Liu J, Sun Y, et al
    First-line therapy for advanced non-small cell lung cancer with activating EGFR mutation: is combined EGFR-TKIs and chemotherapy a better choice?
    Cancer Chemother Pharmacol. 2018 Jan 11. pii: 10.1007/s00280-017-3516.
    PubMed     Abstract available
    
    
    
64. MATHERLY LH, Hou Z, Gangjee A
    The promise and challenges of exploiting the proton-coupled folate transporter for selective therapeutic targeting of cancer.
    Cancer Chemother Pharmacol. 2018;81:1-15.
    PubMed     Abstract available
    
    
    December 2017
65. FEDORCHUK O, Susak Y, Rudyk M, Senchylo N, et al
    Immunological hallmarks of cis-DDP-resistant Lewis lung carcinoma cells.
    Cancer Chemother Pharmacol. 2017 Dec 30. pii: 10.1007/s00280-017-3503.
    PubMed     Abstract available
    
    
    
66. KATAOKA Y, Hirano K, Narabayashi T, Hara S, et al
    Concordance between the response evaluation criteria in solid tumors version 1.1 and the immune-related response criteria in patients with non-small cell lung cancer treated with nivolumab: a multicenter retrospective cohort study.
    Cancer Chemother Pharmacol. 2017 Dec 11. pii: 10.1007/s00280-017-3498.
    PubMed     Abstract available
    
    
    November 2017
67. MASUDA T, Hirano C, Horimasu Y, Nakashima T, et al
    The extent of ground-glass attenuation is a risk factor of chemotherapy-related exacerbation of interstitial lung disease in patients with non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2017 Nov 15. doi: 10.1007/s00280-017-3476.
    PubMed     Abstract available
    
    
    
68. SAKURAI R, Tomizawa Y, Yoshii A, Miura Y, et al
    A phase II study of biweekly gemcitabine and carboplatin in completely resected stage IB-IIIA non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2017 Nov 9. doi: 10.1007/s00280-017-3439.
    PubMed     Abstract available
    
    
    
69. SCHMID U, Liesenfeld KH, Fleury A, Dallinger C, et al
    Population pharmacokinetics of nintedanib, an inhibitor of tyrosine kinases, in patients with non-small cell lung cancer or idiopathic pulmonary fibrosis.
    Cancer Chemother Pharmacol. 2017 Nov 8. doi: 10.1007/s00280-017-3452.
    PubMed     Abstract available
    
    
    
70. MURAKAMI S, Saito H, Kondo T, Ito H, et al
    Phase II study of nedaplatin and irinotecan as adjuvant chemotherapy for completely resected non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2017 Nov 7. doi: 10.1007/s00280-017-3460.
    PubMed     Abstract available
    
    
    October 2017
71. CHEN K, Yu X, Wang H, Huang Z, et al
    Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients.
    Cancer Chemother Pharmacol. 2017 Oct 24. doi: 10.1007/s00280-017-3464.
    PubMed     Abstract available
    
    
    
72. SRINIVASAN G, Sidhu GS, Williamson EA, Jaiswal AS, et al
    Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition.
    Cancer Chemother Pharmacol. 2017;80:861-867.
    PubMed     Abstract available
    
    
    September 2017
73. ZHANG H, Hu B, Wang Z, Zhang F, et al
    miR-181c contributes to cisplatin resistance in non-small cell lung cancer cells by targeting Wnt inhibition factor 1.
    Cancer Chemother Pharmacol. 2017 Sep 27. doi: 10.1007/s00280-017-3435.
    PubMed     Abstract available
    
    
    
74. IKEZAWA Y, Asahina H, Oizumi S, Watanabe M, et al
    A randomized phase II trial of erlotinib vs. S-1 as a third- or fourth-line therapy for patients with wild-type EGFR non-small cell lung cancer (HOT1002).
    Cancer Chemother Pharmacol. 2017 Sep 13. doi: 10.1007/s00280-017-3432.
    PubMed     Abstract available
    
    
    
75. SATO J, Morikawa N, Chiba R, Nihei S, et al
    Case series on the association between blood levels and side effects of afatinib maleate.
    Cancer Chemother Pharmacol. 2017;80:545-553.
    PubMed     Abstract available
    
    
    August 2017
76. REN K, Xu R, Huang J, Zhao J, et al
    Knockdown of long non-coding RNA KCNQ1OT1 depressed chemoresistance to paclitaxel in lung adenocarcinoma.
    Cancer Chemother Pharmacol. 2017;80:243-250.
    PubMed     Abstract available
    
    
    July 2017
77. IMAI H, Sugiyama T, Tamura T, Minemura H, et al
    A retrospective study of amrubicin monotherapy for the treatment of relapsed small cell lung cancer in elderly patients.
    Cancer Chemother Pharmacol. 2017 Jul 31. doi: 10.1007/s00280-017-3403.
    PubMed     Abstract available
    
    
    
78. KENMOTSU H, Ohde Y, Wakuda K, Nakashima K, et al
    Survival data for postoperative adjuvant chemotherapy comprising cisplatin plus vinorelbine after complete resection of non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2017 Jul 31. doi: 10.1007/s00280-017-3400.
    PubMed     Abstract available
    
    
    
79. ZHAO XM, Zhao J, Wu XH, Luo ZG, et al
    Significance of glucocorticoid receptor expression in patients with non-small cell lung cancer treated with pemetrexed-based chemotherapy.
    Cancer Chemother Pharmacol. 2017 Jul 28. doi: 10.1007/s00280-017-3399.
    PubMed     Abstract available
    
    
    
80. KIM HK, Heo MH, Lee HS, Sun JM, et al
    Comparison of RECIST to immune-related response criteria in patients with non-small cell lung cancer treated with immune-checkpoint inhibitors.
    Cancer Chemother Pharmacol. 2017 Jul 21. doi: 10.1007/s00280-017-3396.
    PubMed     Abstract available
    
    
    
81. SHIROYAMA T, Tamiya M, Minami S, Takata S, et al
    Carboplatin plus weekly nanoparticle albumin-bound paclitaxel in elderly patients with previously untreated advanced squamous non-small-cell lung cancer selected based on Mini Nutritional Assessment short-form scores: a multicenter phase 2 study.
    Cancer Chemother Pharmacol. 2017 Jul 7. doi: 10.1007/s00280-017-3385.
    PubMed     Abstract available
    
    
    June 2017
82. XU L, Fu Y, Li Y, Han X, et al
    Cisplatin induces expression of drug resistance-related genes through c-jun N-terminal kinase pathway in human lung cancer cells.
    Cancer Chemother Pharmacol. 2017 Jun 8. doi: 10.1007/s00280-017-3355.
    PubMed     Abstract available
    
    
    
83. PARK S, Kang BW, Lee SJ, Yoon S, et al
    Clinical significance of systemic chemotherapy after curative resection of metachronous pulmonary metastases from colorectal cancer.
    Cancer Chemother Pharmacol. 2017 Jun 8. doi: 10.1007/s00280-017-3348.
    PubMed     Abstract available
    
    
    
84. ASPESLAGH S, Shailubhai K, Bahleda R, Gazzah A, et al
    Phase I dose-escalation study of milciclib in combination with gemcitabine in patients with refractory solid tumors.
    Cancer Chemother Pharmacol. 2017;79:1257-1265.
    PubMed     Abstract available
    
    
    May 2017
85. MILAKI G, Messaritakis I, Koinis F, Kotsakis A, et al
    Prognostic value of chemotherapy-resistant CK19mRNA-positive circulating tumor cells in patients with advanced/metastatic non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2017 May 18. doi: 10.1007/s00280-017-3339.
    PubMed     Abstract available
    
    
    
86. CHEN X, Liu L, Guo Z, Liang W, et al
    UGT1A1 polymorphisms with irinotecan-induced toxicities and treatment outcome in Asians with Lung Cancer: a meta-analysis.
    Cancer Chemother Pharmacol. 2017 May 13. doi: 10.1007/s00280-017-3306.
    PubMed     Abstract available
    
    
    
87. OKUDA Y, Sato K, Sudo K, Hasegawa Y, et al
    Low plasma concentration of gefitinib in patients with EGFR exon 21 L858R point mutations shortens progression-free survival.
    Cancer Chemother Pharmacol. 2017;79:1013-1020.
    PubMed     Abstract available
    
    
    April 2017
88. FUJIWARA T, Kenmotsu H, Naito T, Kawamura T, et al
    The incidence and risk factors of febrile neutropenia in chemotherapy-naive lung cancer patients receiving etoposide plus platinum.
    Cancer Chemother Pharmacol. 2017 Apr 28. doi: 10.1007/s00280-017-3324.
    PubMed     Abstract available
    
    
    
89. NISHIJIMA-FUTAMI Y, Minami S, Futami S, Koba T, et al
    Phase II study of S-1 plus bevacizumab combination therapy for patients previously treated for non-squamous non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2017 Apr 28. doi: 10.1007/s00280-017-3321.
    PubMed     Abstract available
    
    
    
90. LAU YY, Gu W, Lin T, Viraswami-Appanna K, et al
    Assessment of drug-drug interaction potential between ceritinib and proton pump inhibitors in healthy subjects and in patients with ALK-positive non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2017 Apr 19. doi: 10.1007/s00280-017-3308.
    PubMed     Abstract available
    
    
    
91. XIANG T, Kang X, Gong Z, Bai W, et al
    XPG genetic polymorphisms and clinical outcome of patients with advanced non-small cell lung cancer under platinum-based treatment: a meta-analysis of 12 studies.
    Cancer Chemother Pharmacol. 2017;79:791-800.
    PubMed     Abstract available
    
    
    March 2017
92. WAKELEE HA, Gettinger S, Engelman J, Janne PA, et al
    A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2017 Mar 28. doi: 10.1007/s00280-017-3283.
    PubMed     Abstract available
    
    
    
93. JANG J, Kim HK, Cho BC, Lee KH, et al
    Randomized phase II study comparing weekly docetaxel-cisplatin vs. gemcitabine-cisplatin in elderly or poor performance status patients with advanced non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2017 Mar 24. doi: 10.1007/s00280-017-3289.
    PubMed     Abstract available
    
    
    
94. MORCOS PN, Bogman K, Hubeaux S, Sturm-Pellanda C, et al
    Effect of alectinib on cardiac electrophysiology: results from intensive electrocardiogram monitoring from the pivotal phase II NP28761 and NP28673 studies.
    Cancer Chemother Pharmacol. 2017;79:559-568.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: